Trial Profile
Safety and efficacy of extended-release methylphenidate (Oros) in patients with attention-deficit hyperactivity disorder: A retrospective cohort study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2016
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Therapeutic Use
- 08 Oct 2016 New trial record